

# Elin S Gray

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/6517408/elin-s-gray-publications-by-citations.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

107  
papers

5,015  
citations

38  
h-index

70  
g-index

120  
ext. papers

5,922  
ext. citations

6  
avg. IF

5.25  
L-index

#	Paper	IF	Citations
107	The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. <i>Journal of Virology</i> , <b>2011</b> , 85, 4828-40	6.6	348
106	Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. <i>Journal of Virology</i> , <b>2011</b> , 85, 9998-10009	6.6	342
105	Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. <i>Journal of Virology</i> , <b>2008</b> , 82, 11651-68	6.6	305
104	Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. <i>Journal of Virology</i> , <b>2007</b> , 81, 6187-96	6.6	242
103	Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. <i>Oncotarget</i> , <b>2015</b> , 6, 42008-18	3.3	238
102	Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. <i>Nature Medicine</i> , <b>2012</b> , 18, 1688-92	50.5	234
101	Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. <i>PLoS Pathogens</i> , <b>2009</b> , 5, e1000598	7.6	184
100	Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. <i>Journal of Virology</i> , <b>2009</b> , 83, 8925-37	6.6	149
99	Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. <i>Journal of Virology</i> , <b>2011</b> , 85, 11502-19	6.6	148
98	Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes. <i>PLoS Pathogens</i> , <b>2013</b> , 9, e1003738	7.6	147
97	The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection. <i>Journal of Virology</i> , <b>2008</b> , 82, 1860-9	6.6	132
96	Autoantibody Production in Cancer--The Humoral Immune Response toward Autologous Antigens in Cancer Patients. <i>Autoimmunity Reviews</i> , <b>2016</b> , 15, 477-83	13.6	130
95	Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop. <i>Journal of Virology</i> , <b>2011</b> , 85, 3128-41	6.6	128
94	Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting. <i>PLoS ONE</i> , <b>2011</b> , 6, e23532	3.7	123
93	The development of CD4 binding site antibodies during HIV-1 infection. <i>Journal of Virology</i> , <b>2012</b> , 86, 7588-95	6.6	105
92	Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region. <i>Journal of Virology</i> , <b>2009</b> , 83, 11265-74	6.6	84
91	Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma. <i>Cancer Letters</i> , <b>2017</b> , 404, 62-69	9.9	83

90	Detection of BRAF-V600E and V600K in melanoma circulating tumour cells by droplet digital PCR. <i>Clinical Biochemistry</i> , <b>2015</b> , 48, 999-1002	3.5	82
89	Mannose-rich glycosylation patterns on HIV-1 subtype C gp120 and sensitivity to the lectins, Griffithsin, Cyanovirin-N and Scytovirin. <i>Virology</i> , <b>2010</b> , 402, 187-96	3.6	82
88	P04-06. Evolution of an anti-MPER gp41 antibody response that mediates broad HIV-1 cross-neutralization. <i>Retrovirology</i> , <b>2009</b> , 6,	3.6	78
87	P09-04. Charge changes in the alpha2-helix in the C3 region of the HIV-1 subtype C envelope mediate neutralization escape. <i>Retrovirology</i> , <b>2009</b> , 6,	3.6	78
86	High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination. <i>Virology</i> , <b>2009</b> , 387, 414-26	3.6	74
85	Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B. <i>PLoS Medicine</i> , <b>2006</b> , 3, e255	11.6	66
84	Circulating Melanoma Cell Subpopulations: Their Heterogeneity and Differential Responses to Treatment. <i>Journal of Investigative Dermatology</i> , <b>2015</b> , 135, 2040-2048	4.3	57
83	Multiple pathways of escape from HIV broadly cross-neutralizing V2-dependent antibodies. <i>Journal of Virology</i> , <b>2013</b> , 87, 4882-94	6.6	55
82	Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses. <i>Cell Host and Microbe</i> , <b>2015</b> , 18, 354-62	23.4	53
81	Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients. <i>BMC Cancer</i> , <b>2018</b> , 18, 726	4.8	50
80	Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individual. <i>Journal of Virology</i> , <b>2011</b> , 85, 7719-29	6.6	50
79	Specificity of the autologous neutralizing antibody response. <i>Current Opinion in HIV and AIDS</i> , <b>2009</b> , 4, 358-63	4.2	50
78	Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?. <i>Cancer Letters</i> , <b>2020</b> , 468, 59-71	9.9	49
77	Evaluation of a multi-marker immunomagnetic enrichment assay for the quantification of circulating melanoma cells. <i>Journal of Translational Medicine</i> , <b>2012</b> , 10, 192	8.5	47
76	Binding of the mannose-specific lectin, griffithsin, to HIV-1 gp120 exposes the CD4-binding site. <i>Journal of Virology</i> , <b>2011</b> , 85, 9039-50	6.6	44
75	Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours. <i>Nature Communications</i> , <b>2020</b> , 11, 2408	17.4	42
74	The lectins griffithsin, cyanovirin-N and scytovirin inhibit HIV-1 binding to the DC-SIGN receptor and transfer to CD4(+) cells. <i>Virology</i> , <b>2012</b> , 423, 175-86	3.6	42
73	Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodies. <i>Virology</i> , <b>2007</b> , 368, 172-81	3.6	42

72	Monitoring changes in circulating tumour cells as a prognostic indicator of overall survival and treatment response in patients with metastatic melanoma. <i>BMC Cancer</i> , <b>2014</b> , 14, 423	4.8	40
71	N-linked glycan modifications in gp120 of human immunodeficiency virus type 1 subtype C render partial sensitivity to 2G12 antibody neutralization. <i>Journal of Virology</i> , <b>2007</b> , 81, 10769-76	6.6	40
70	Sensitive droplet digital PCR method for detection of promoter mutations in cell free DNA from patients with metastatic melanoma. <i>Oncotarget</i> , <b>2017</b> , 8, 78890-78900	3.3	39
69	4E10-resistant variants in a human immunodeficiency virus type 1 subtype C-infected individual with an anti-membrane-proximal external region-neutralizing antibody response. <i>Journal of Virology</i> , <b>2008</b> , 82, 2367-75	6.6	34
68	Isolation and detection of circulating tumour cells from metastatic melanoma patients using a slanted spiral microfluidic device. <i>Oncotarget</i> , <b>2017</b> , 8, 67355-67368	3.3	34
67	Heat stress: a risk factor for skin carcinogenesis. <i>Cancer Letters</i> , <b>2013</b> , 337, 35-40	9.9	32
66	UCLA1, a synthetic derivative of a gp120 RNA aptamer, inhibits entry of human immunodeficiency virus type 1 subtype C. <i>Journal of Virology</i> , <b>2012</b> , 86, 4989-99	6.6	30
65	PD-L1 Expression on Circulating Tumor Cells May Be Predictive of Response to Pembrolizumab in Advanced Melanoma: Results from a Pilot Study. <i>Oncologist</i> , <b>2020</b> , 25, e520-e527	5.7	29
64	Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity. <i>EBioMedicine</i> , <b>2016</b> , 12, 196-207	8.8	28
63	Structure and molecular interactions of a unique antitumor antibody specific for N-glycolyl GM3. <i>Journal of Biological Chemistry</i> , <b>2004</b> , 279, 5597-603	5.4	28
62	Melanoma circulating tumor cells: Benefits and challenges required for clinical application. <i>Cancer Letters</i> , <b>2018</b> , 424, 1-8	9.9	27
61	Locus-specific concordance of genomic alterations between tissue and plasma circulating tumor DNA in metastatic melanoma. <i>Molecular Oncology</i> , <b>2019</b> , 13, 171-184	7.9	27
60	A monoclonal antibody against NeuGc-containing gangliosides contains a regulatory idiotope involved in the interaction with B and T cells. <i>Molecular Immunology</i> , <b>2002</b> , 39, 103-12	4.3	26
59	Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. <i>Frontiers in Oncology</i> , <b>2013</b> , 3, 54	5.3	25
58	Droplet Digital PCR for Mutation Detection in Formalin-Fixed, Paraffin-Embedded Melanoma Tissues: A Comparison with Sanger Sequencing and Pyrosequencing. <i>Journal of Molecular Diagnostics</i> , <b>2018</b> , 20, 240-252	5.1	24
57	Detection and prognostic role of heterogeneous populations of melanoma circulating tumour cells. <i>British Journal of Cancer</i> , <b>2020</b> , 122, 1059-1067	8.7	23
56	Mechanisms of HIV-1 subtype C resistance to GRFT, CV-N and SVN. <i>Virology</i> , <b>2013</b> , 446, 66-76	3.6	21
55	Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 5926-5933	12.9	21

54	Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 4064-4071	12.9	20
53	A Panel of Circulating MicroRNAs Detects Uveal Melanoma With High Precision. <i>Translational Vision Science and Technology</i> , <b>2019</b> , 8, 12	3.3	20
52	A diagnostic autoantibody signature for primary cutaneous melanoma. <i>Oncotarget</i> , <b>2018</b> , 9, 30539-30553	3.3	19
51	South African HIV-1 subtype C transmitted variants with a specific V2 motif show higher dependence on $\beta$ 7 for replication. <i>Retrovirology</i> , <b>2015</b> , 12, 54	3.6	18
50	Heat-mediated reduction of apoptosis in UVB-damaged keratinocytes in vitro and in human skin ex vivo. <i>BMC Dermatology</i> , <b>2016</b> , 16, 6	2.1	17
49	Exercise-induced myokines and their effect on prostate cancer. <i>Nature Reviews Urology</i> , <b>2021</b> , 18, 519-542	5.5	14
48	Genomic Analysis of Circulating Tumor DNA Using a Melanoma-Specific UltraSEEK Oncogene Panel. <i>Journal of Molecular Diagnostics</i> , <b>2019</b> , 21, 418-426	5.1	13
47	Monitoring melanoma recurrence with circulating tumor DNA: a proof of concept from three case studies. <i>Oncotarget</i> , <b>2019</b> , 10, 113-122	3.3	13
46	A comparative study of extracellular vesicle-associated and cell-free DNA and RNA for HPV detection in oropharyngeal squamous cell carcinoma. <i>Scientific Reports</i> , <b>2020</b> , 10, 6083	4.9	12
45	Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary models. <i>Virology Journal</i> , <b>2013</b> , 10, 347	6.1	12
44	Immunomagnetic-Enriched Subpopulations of Melanoma Circulating Tumour Cells (CTCs) Exhibit Distinct Transcriptome Profiles. <i>Cancers</i> , <b>2019</b> , 11,	6.6	11
43	Stopping targeted therapy for complete responders in advanced BRAF mutant melanoma. <i>Scientific Reports</i> , <b>2020</b> , 10, 18878	4.9	11
42	Tumour PD-L1 Expression in Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. <i>Cells</i> , <b>2020</b> , 9,	7.9	11
41	Clinical Application of Circulating Tumor Cells and Circulating Tumor DNA in Uveal Melanoma. <i>JCO Precision Oncology</i> , <b>2018</b> , 2,	3.6	11
40	Prognostic value of HLA-I homozygosity in patients with non-small cell lung cancer treated with single agent immunotherapy <b>2020</b> , 8,		9
39	Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review. <i>Biochimica Et Biophysica Acta - General Subjects</i> , <b>2021</b> , 1865, 129736	4	9
38	Circulating tumour DNA (ctDNA) as a biomarker in metachronous melanoma and colorectal cancer- a case report. <i>BMC Cancer</i> , <b>2019</b> , 19, 1109	4.8	7
37	A standardised protocol for the evaluation of small extracellular vesicles in plasma by imaging flow cytometry. <i>Journal of Immunological Methods</i> , <b>2019</b> , 468, 61-66	2.5	6

36	Differences in HIV type 1 neutralization breadth in 2 geographically distinct cohorts in Africa. <i>Journal of Infectious Diseases</i> , <b>2015</b> , 211, 1461-6	7	6
35	Evolution of antibody landscape and viral envelope escape in an HIV-1 CRF02_AG infected patient with 4E10-like antibodies. <i>Retrovirology</i> , <b>2009</b> , 6, 113	3.6	6
34	SIRT1 activation mediates heat-induced survival of UVB damaged Keratinocytes. <i>BMC Dermatology</i> , <b>2017</b> , 17, 8	2.1	5
33	The Prognostic Impact of Circulating Tumour DNA in Melanoma Patients Treated with Systemic Therapies-Beyond Mutant Detection. <i>Cancers</i> , <b>2020</b> , 12,	6.6	5
32	Circulating Tumor DNA Reflects Uveal Melanoma Responses to Protein Kinase C Inhibition. <i>Cancers</i> , <b>2021</b> , 13,	6.6	5
31	Prognostic Relevance of CCDC88C (Daple) Transcripts in the Peripheral Blood of Patients with Cutaneous Melanoma. <i>Scientific Reports</i> , <b>2018</b> , 8, 18036	4.9	5
30	Myokine Expression and Tumor-suppressive Effect of Serum following 12 Weeks of Exercise in Prostate Cancer Patients on ADT. <i>Medicine and Science in Sports and Exercise</i> , <b>2021</b> ,	1.2	5
29	Is the Blood an Alternative for Programmed Cell Death Ligand 1 Assessment in Non-Small Cell Lung Cancer?. <i>Cancers</i> , <b>2019</b> , 11,	6.6	4
28	Erdheim-Chester disease associated with a novel, complex BRAF p.Thr599_Val600delinsArgGlu mutation. <i>BMJ Case Reports</i> , <b>2017</b> , 2017,	0.9	4
27	The Epigenetic landscape of Circulating tumour cells. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , <b>2021</b> , 1875, 188514	11.2	4
26	Changes in plasma hydroxyproline and plasma cell-free DNA concentrations after higher- versus lower-intensity eccentric cycling. <i>European Journal of Applied Physiology</i> , <b>2021</b> , 121, 1087-1097	3.4	4
25	Tumour- associated autoantibodies as prognostic cancer biomarkers- a review.. <i>Autoimmunity Reviews</i> , <b>2022</b> , 21, 103041	13.6	3
24	UCLA1 aptamer inhibition of human immunodeficiency virus type 1 subtype C primary isolates in macrophages and selection of resistance. <i>Biochemistry and Biophysics Reports</i> , <b>2016</b> , 7, 408-414	2.2	3
23	Identification and characterisation of putative drug binding sites in human ATP-binding cassette B5 (ABCB5) transporter. <i>Computational and Structural Biotechnology Journal</i> , <b>2021</b> , 19, 691-704	6.8	3
22	Role of Serum Vascular Endothelial Growth Factor (VEGF) as a Potential Biomarker of Response to Immune Checkpoint Inhibitor Therapy in Advanced Melanoma: Results of a Pilot Study. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 1041	5.3	2
21	Low-Pass Whole-Genome Sequencing as a Method of Determining Copy Number Variations in Uveal Melanoma Tissue Samples. <i>Journal of Molecular Diagnostics</i> , <b>2020</b> , 22, 429-434	5.1	2
20	Arterial or Venous: Where Are the Circulating Tumor Cells?. <i>EBioMedicine</i> , <b>2015</b> , 2, 1596-7	8.8	2
19	Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection. <i>Virology</i> , <b>2012</b> , 433, 410-20	3.6	2

18	Exercise in advanced prostate cancer elevates myokine levels and suppresses in-vitro cell growth.. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2022</b> ,	6.2	2
17	Investigating primary preservice teachersSultraviolet radiation awareness and perceived ability to teach sun safety. <i>Health Promotion Journal of Australia</i> , <b>2021</b> , 32 Suppl 2, 178-184	1.7	2
16	Detection of clinical progression through plasma ctDNA in metastatic melanoma patients: a comparison to radiological progression. <i>British Journal of Cancer</i> , <b>2021</b> ,	8.7	2
15	Intra- and intertumoral heterogeneity of liver metastases in a patient with uveal melanoma revealed by single-cell RNA sequencing. <i>Journal of Physical Education and Sports Management</i> , <b>2021</b> , 7,	2.8	2
14	Multi-Marker Immunomagnetic Enrichment of Circulating Melanoma Cells. <i>Methods in Molecular Biology</i> , <b>2021</b> , 2265, 213-222	1.4	2
13	Lab-on-chip platform for circulating tumor cells isolation <b>2015</b> ,		1
12	Detection of splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies. <i>Oncotarget</i> , <b>2020</b> , 11, 4016-4027	3.3	1
11	Repurposing nano-enabled polymeric scaffolds for tumor-wound management and 3D tumor engineering. <i>Regenerative Medicine</i> , <b>2020</b> , 15, 2229-2247	2.5	1
10	Entry inhibition of HIV-1 subtype C isolates <b>2007</b> , 119-131		1
9	Circulating Tumour DNA in Advanced Melanoma Patients Ceasing PD1 Inhibition in the Absence of Disease Progression. <i>Cancers</i> , <b>2020</b> , 12,	6.6	1
8	Multi-Marker Immunofluorescent Staining and PD-L1 Detection on Circulating Tumour Cells from Ovarian Cancer Patients.. <i>Cancers</i> , <b>2021</b> , 13,	6.6	1
7	Application of multiplex ligation-dependent probe amplification (MLPA) and low pass whole genome sequencing (LP-WGS) to the classification / characterisation of low grade glioneuronal tumours.. <i>Pathology Research and Practice</i> , <b>2021</b> , 229, 153724	3.4	0
6	Circulating Tumor Cells as Biomarkers in Cancer. <i>Biomarkers in Disease</i> , <b>2015</b> , 31-51		0
5	Transcript-Based Detection of Circulating Melanoma Cells. <i>Methods in Molecular Biology</i> , <b>2021</b> , 2265, 235-245	1.4	0
4	Evaluation of PD-L1 expression on circulating tumour cells in small-cell lung cancer.. <i>Translational Lung Cancer Research</i> , <b>2022</b> , 11, 440-451	4.4	0
3	Circulating Tumor Cells as Biomarkers in Cancer <b>2014</b> , 1-17		
2	Associations of Physical Activity and Exercise with Health-related Outcomes in Patients with Melanoma During and After Treatment: A Systematic Review. <i>Integrative Cancer Therapies</i> , <b>2021</b> , 20, 15347354211040757	3	
1	Isolation and Quantification of Plasma Circulating Tumor DNA from Melanoma Patients. <i>Methods in Molecular Biology</i> , <b>2021</b> , 2265, 247-263	1.4	

